Unicycive Therapeutics In... (UNCY)
NASDAQ: UNCY
· Real-Time Price · USD
4.71
0.08 (1.73%)
At close: Aug 15, 2025, 3:59 PM
4.72
0.32%
After-hours: Aug 15, 2025, 07:57 PM EDT
Unicycive Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 570K | -21.52M | -4.1M | 3.93M | -20.96M | -7.8M | -4.33M | -3.84M | -14.57M | -5.33M | -5.56M | -3.64M | -3.54M | -2.75M | -5.2M | -1.1M | -964K |
Depreciation & Amortization | 135K | 134K | 123K | -113K | 284K | 82K | 79K | 78K | 45K | 42K | 40K | 40K | 39K | 1K | n/a | n/a | n/a |
Stock-Based Compensation | 563K | 582K | 605K | 641K | 522K | 550K | 929K | 144K | 144K | 197K | 266K | 294K | 290K | 231K | 239K | 294K | 202K |
Other Working Capital | n/a | 731K | -3.5M | 108K | 1.07M | 694K | -1.19M | -1.16M | 193K | -375K | -266K | 325K | 227K | 430K | -1.72M | 45K | -99K |
Other Non-Cash Items | n/a | 12.56M | -1.75M | -10.88M | 11.81M | 1.89M | -1.4M | -282K | 10.38M | 21K | -1.65M | 406K | 307K | -91K | 2.77M | 441K | 271K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -287K | n/a | n/a | n/a | n/a | 1.65M | -406K | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | 1.7M | -4.13M | 108K | 1.89M | 1.12M | 299K | -1.6M | 91K | -1.02M | 1.69M | 255K | 251K | 1.21M | -1.28M | 148K | -182K |
Operating Cash Flow | -8.9M | -6.55M | -9.25M | -6.32M | -6.46M | -4.44M | -4.42M | -5.5M | -3.92M | -6.08M | -3.56M | -3.05M | -2.96M | -1.4M | -3.47M | -217K | -673K |
Capital Expenditures | -16K | -22K | -24K | -20K | -6K | n/a | n/a | -12K | n/a | -2K | n/a | n/a | -2K | -29K | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -16K | -22K | -24K | -20K | -6K | n/a | n/a | -12K | n/a | -2K | n/a | n/a | -2K | -29K | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 174K | 701K |
Common Stock Repurchased | n/a | n/a | -13.09B | 13.09B | n/a | -11.66B | 10.32B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | -208K | n/a | -1.09M | -208K | -867K | n/a | n/a | -192K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 2.55M | -158K | -157K | 284K | -496K | -205K | -51K | n/a | -2.39M | -482K | n/a | n/a | n/a | 18.72M | 21.48M | -103K | 119K |
Financial Cash Flow | 2.55M | 365K | -157K | -811K | 45.69M | -205K | -51K | n/a | 27.8M | -471K | n/a | n/a | n/a | n/a | 21.48M | 71K | 820K |
Net Cash Flow | -6.37M | -6.21M | -9.43M | -7.15M | 39.23M | -4.64M | -4.47M | -5.51M | 23.88M | -6.55M | -3.56M | -3.05M | -2.96M | -1.43M | 18.01M | -146K | 147K |
Free Cash Flow | -8.92M | -6.57M | -9.28M | -6.34M | -6.46M | -4.44M | -4.42M | -5.51M | -3.92M | -6.09M | -3.56M | -3.05M | -2.96M | -1.43M | -3.47M | -217K | -673K |